Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan.
Publisher s Platform: What you need to know about E coli during an Outbreak foodsafetynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foodsafetynews.com Daily Mail and Mail on Sunday newspapers.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® and $91 million for EMPAVELI® Strong SYFOVRE launch, with more than 160,000 total doses distributed in 2023.
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U S Net Product Revenues tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U S Net Product Revenues marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.